Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2016 / Article
Special Issue

Oxidative Stress and Cancer: Advances and Challenges

View this Special Issue

Review Article | Open Access

Volume 2016 |Article ID 9875298 | https://doi.org/10.1155/2016/9875298

Zhiqi Wang, Sai Li, Yu Cao, Xuefei Tian, Rong Zeng, Duan-Fang Liao, Deliang Cao, "Oxidative Stress and Carbonyl Lesions in Ulcerative Colitis and Associated Colorectal Cancer", Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 9875298, 15 pages, 2016. https://doi.org/10.1155/2016/9875298

Oxidative Stress and Carbonyl Lesions in Ulcerative Colitis and Associated Colorectal Cancer

Academic Editor: Lokesh Deb
Received03 Jun 2015
Revised14 Oct 2015
Accepted25 Oct 2015
Published28 Dec 2015


Oxidative stress has long been known as a pathogenic factor of ulcerative colitis (UC) and colitis-associated colorectal cancer (CAC), but the effects of secondary carbonyl lesions receive less emphasis. In inflammatory conditions, reactive oxygen species (ROS), such as superoxide anion free radical (), hydrogen peroxide (H2O2), and hydroxyl radical (), are produced at high levels and accumulated to cause oxidative stress (OS). In oxidative status, accumulated ROS can cause protein dysfunction and DNA damage, leading to gene mutations and cell death. Accumulated ROS could also act as chemical messengers to activate signaling pathways, such as NF-κB and p38 MAPK, to affect cell proliferation, differentiation, and apoptosis. More importantly, electrophilic carbonyl compounds produced by lipid peroxidation may function as secondary pathogenic factors, causing further protein and membrane lesions. This may in turn exaggerate oxidative stress, forming a vicious cycle. Electrophilic carbonyls could also cause DNA mutations and breaks, driving malignant progression of UC. The secondary lesions caused by carbonyl compounds may be exceptionally important in the case of host carbonyl defensive system deficit, such as aldo-keto reductase 1B10 deficiency. This review article updates the current understanding of oxidative stress and carbonyl lesions in the development and progression of UC and CAC.

1. Introduction

Reactive oxygen species (ROS) refer to a class of special oxygen chemical forms or oxygen-containing compounds that have much higher chemical activity than the oxygen. Oxidative stress (OS) occurs if the generation of ROS exceeds the defensive capability of the antioxidant system in the cell [1]. As a largest endocrine and immune organ, the intestinal tract abundant with microorganisms is important in stress response, such as oxidative stress [2]. Superoxide anion free radical () and nitric oxide free radical () are two main endogenous reactive oxygen/nitrogen species (ROS/RNS), from which other reactive free radicals, such as hydrogen peroxide (H2O2), hydroxyl radical (), and peroxynitrite anion (ONOO), are derived [3]. There are several sources of ROS in the digestive tract [4]. Luminal microbes produce a large amount of ROS; inside cells, superoxide anion, hydrogen peroxide, and hydroxyl radicals are produced as byproducts of mitochondrial respiration in aerobic metabolism and in cytochrome P450 detoxifying reactions; and in the process of chronic inflammation, a large amount of ROS is produced by neutrophil phagocytosis of bacteria, granular materials, or soluble irritants [5, 6].

In normal condition, intestinal ROS have bactericidal effects, participating in the intestinal defensive function. However, oxidative stress derived from excessive ROS production over the buffering capability of antioxidant defense in the host would cause lipid peroxidation, intestinal mucosal barrier damage, bacterial translocation, and inflammatory response [2, 7]. Ulcerative colitis (UC) is a type of chronic inflammatory bowel disease (IBD) in which oxidative stress plays a critical role in its pathogenesis and malignant progression to colorectal cancer (CRC) [8, 9]. UC affects the distal colon and rectum but often extends to the proximal colon and eventually to the whole colon. Clinically, patients with UC usually experience an intermittent course for a lifetime and colectomy is the only curative option [10, 11]. A worse scenario of UC is the increased risk of developing colorectal cancer, so-called colitis-associated colorectal cancer (CAC) [12]. This review article focuses on the oxidative stress and secondary carbonyl (lipid peroxide) lesions in the pathogenesis of UC and CAC.

2. Oxidative Stress and Carbonyl Lesions in Ulcerative Colitis

UC is essentially an immune-inflammatory disease. Inflammation is a process that consists of a series of protective responses, such as immune cell infiltration and cytokine expression, to eliminate pathogens/insults and initiate damage repair of the tissue. Acute inflammation is the immediate response of the body to pathogens and characterized with recruitment of leukocytes, particularly granulocytes. Chronic inflammation is a prolonged inflammatory process and characterized by simultaneous damage and healing of tissues at the inflammatory spot, resulting in a progressive shift of cell types. Therefore, chronic inflammation often leads to progressive diseases in the host [13].

Ulcerative colitis (UC) is a chronic inflammation described with remission and reactivation [10]. In active phase, UC is characterized with diffusive inflammatory cell infiltration and small intestinal mucosal crypt abscesses. In the inflammatory colon, mucosa, submucosa, and lamina propria are often infiltrated with neutrophils, lymphocytes, plasma cells, and eosinophils [14]. The infiltrated neutrophils produce a large amount of ROS, triggering oxidative stress, and proteolytic enzymes. The proteolytic enzymes and ROS act on endothelial cells and cause cell injury and subsequent epithelial barrier permeability and luminal pathogen invasion, which in turn exaggerate inflammatory cell infiltration and inflammatory damage, eventually leading to intestinal mucosal necrosis and ulceration [15]. Meanwhile, epithelial regeneration starts to cover the ulcerative area under stimulation of mitogenic cytokines and prostaglandins produced in inflammatory response. In this circumstance, intestinal mucosal hyperemia, edema, and hyperplasia polyps may appear.

Etiopathology of UC is complicated, including bacterial or viral infection, changes of colon microbiota, excessive immune response, and oxidative stress injury [16, 17]. Host genetic factors also play an etiological role in the development and progression of UC. It has been reported that the chromosomal loci 3, 7, and 12 in humans are associated with individual sensitivity to inflammatory bowel disease, including UC [18]. Recent studies from our laboratory have demonstrated that aldo-keto reductase 1B10 (AKR1B10) is a potential etiopathogenic factor of UC and CAC [19]. Among these etiopathological factors, the abnormal immune response is considered a key of UC. The normal colon mucosa plays an immune, endocrine, and barrier function. Injuries occurring in the intestinal mucosa insult its barrier function; increased intestinal mucosal permeability allows microbes and antigens to invade and excessively stimulate immune response, triggering intestinal inflammation. Excessive ROS are produced leading to oxidative stress during the inflammatory response, exaggerating inflammatory lesions in the pathogenesis of UC.

2.1. Redox in the Intestine

In the intestine, main ROS include hydroxyl free radical (), superoxide anion radical (), and hydrogen peroxide (H2O2) while superoxide dismutase (SOD), glutathione peroxidase (GSH-PX), and catalase (CAT) are main antioxidant enzymes [20]. Peroxisomes are important organelles in biological oxidation in cells and participate in production and clearance of free radicals. Peroxisomes are enriched with hydrogen peroxide enzymes, oxidases, and peroxidases [21, 22]. Oxidases catalyze β-oxidation of fatty acids for energetic metabolism, producing H2O2. H2O2 is in turn transformed into or other active free radicals [23]. In addition, xanthine oxidase and uric acid oxidase produce electronics in oxidative metabolic pathways [24, 25]. Hydrogen peroxide enzyme and SOD reduce H2O2 into H2O. In the process of chronic intestinal inflammation, a large amount of ROS, such as and H2O2, is produced by neutrophils during phagocytosis. This phagocytic process activates nicotinamide adenine dinucleotide phosphate oxidase (NOX) in the membrane, leading to rapid depletion of oxygen and production of superoxide anion [5, 6].

Cells evolve an antioxidant defense system to maintain homeostasis between the oxidant and antioxidant species [26, 27]. Excessive generation of free radicals beyond the capacity of defense leads to failure of this homeostatic process and oxidative injuries, such as lipid peroxidation and DNA damage, so-called oxidative stress. The antioxidant defense system in cells consists of enzymatic and nonenzymatic antioxidant molecules (Table 1). In addition to the endogenous cellular antioxidant species, natural food is also an important resource of antioxidants. For example, quercetin (3,5,7,3′,4′, pentahydroxyflavone), a flavonoid present in numerous fruits and vegetables, demonstrates appreciable antioxidant activity by eliminating free radicals and quenching singlet oxygen [28]. Resveratrol, a phenolic substance in red wines, is also a natural antioxidant and anti-inflammatory molecule [29].

Oxidant species

Reactive oxygen species (ROS)Superoxide anion ()
Peroxide ()
Hydrogen peroxide (H2O2)
Hydroxyl radical ()
Hydroxyl ion ()

Reactive nitrogen species (RNS)Nitric oxide ()
Peroxynitrite ()
Nitrogen dioxide ()
Dinitrogen trioxide (N2O3)
Nitrosoperoxycarbonate ()

ROS resourcesMitochondrial electron transition
Enzyme reactions: peroxisomal oxidases, cytochrome P-450, NAD(P)H oxidases, and xanthine oxidase
Xenobiotics, drugs, and radiation: cisplatin, doxorubicin, and so forth.

RNS resourcesNitric oxide () from nitric oxide synthase 2 (NOS2)
Other RNS from reaction of nitric oxide () with superoxide anion () and other reactive species.

Antioxidant defense

Nonenzymatic antioxidantsGlutathione (GSH)
Coenzyme Q (CoQ)
Uric acid

Enzymatic antioxidantsSuperoxide dismutase (SOD)
Catalase (CAT)
Peroxiredoxin (Prx)
Glutathione reductase (GR)
Glutathione peroxidases (GPx)
Glutathione-S-transferases (GST)
Thioredoxin and thioredoxin reductase

Natural (food) antioxidantsVitamin A/C/E

2.2. Oxidative Stress Insults in Ulcerative Colitis

While a basal level of ROS may play a protective role in the intestine, the oxidative stress derived from imbalance between ROS production and antioxidant system is harmful, being an important pathogenic factor of UC. ROS are highly active chemical forms that target macromolecules, such as proteins, lipids, and nucleic acids, leading to lipid peroxidation, protein dysfunction, and DNA mutations (Figure 1). Therefore, excessive ROS cause cell and tissue damage, exaggerate inflammation, and lead to far-reaching effects, such as carcinogenesis. Herein we will discuss the protein and lipid damage and cellular effects induced by oxidative stress. Nuclei acid damage and carcinogenic effects of oxidative stress will be addressed in Section 3.

2.2.1. Protein Damage Induced by Oxidative Stress

Oxidative stress insults proteins. Highly active ROS can readily interact with protein amino acid residues, such as His, Pro, Trp, Cys, and Tyr residues, and cause protein structure changes, polypeptide chain cracking, and loss of the biological activity. For example, ROS can oxidize sulfhydryl groups (-SH) in the amino acid residues to form disulfide bonds (-S-S-) and cross-link (Figure 1). ROS could also attack the methyl-sulfide group (CH3-S-) in methionine (Met) and affect hydrolysis and carbonylation of proteins [30, 31].

2.2.2. Lipid Peroxidation Triggered by Oxidative Stress

Lipid peroxidation (LPO) is a serious cellular damage. Reactive ROS readily bind to unsaturated fatty acids in lipids that contain multiple double bonds, “steal” electrons, and trigger a free radical chain reaction (Figure 1). This oxidative process usually consists of initiation (production of a fatty acid radical), propagation (creation of a peroxyl-fatty acid radical), and termination (production of electrophilic carbonyls) [32]. This lipid peroxidation process produces two major biological effects, that is, direct membrane damage and permeability and production of lipid peroxides [33]. The common lipid peroxides created by lipid peroxidation include malondialdehyde (MAD), 4-hydroxynonenal (HNE), crotonaldehyde, and acrolein [34]. These lipid peroxides are α,β-unsaturated and highly reactive to cellular proteins and nucleic acids. In UC pathogenesis, lipid peroxides are important secondary injury factors of oxidative stress.

Phospholipids are primary ingredients of cell and organelle membrane and are enriched with unsaturated fatty acids. Therefore, the lipid peroxidation induced by oxidative stress mainly occurs in the membrane, and attacking by ROS would lead to direct structural and functional changes of membranes [33]. Mitochondrial membrane is the site of the respiratory chain that generates ROS in the normal cells. Therefore, mitochondria are the main organelles that are produced and attacked by ROS [35]. In the status of oxidative stress, excessive ROS attack oxidation respiratory chain and lead to obstacle of oxidative phosphorylation, producing more ROS. Excessive ROS also make Ca2+ overload in the mitochondria and lead to mitochondrial membrane depolarization and permeability, releasing free radicals into cytoplasm and causing cellular damage in general. Increased membrane permeability also releases cytochrome C (Cyt-C) and apoptosis inducing factor (AIF) into cytoplasm and activates caspase cascade for apoptosis [36, 37]. Therefore, in oxidative status ROS production by respiratory chain, mitochondrial membrane insults, and ROS release into cytoplasm form a vicious cycle, causing cell death and tissue injury. We will discuss the lesions induced by lipid peroxides in Section 2.3.

2.2.3. Cell Signaling Triggered by Oxidative Stress

ROS could function as second messengers to activate intracellular signaling pathways, such as NF-κB, a major modulator of UC [3842]. In the normal intestinal epithelium, NF-κB maintains intestinal epithelial barrier function and coordinates epithelial immune response to microorganisms. On the other hand, as transcription factors, deregulation of NF-κB signaling, such as oxidative activation, stimulates expression of a variety of proinflammatory cytokines in the intestinal epithelial cells, such as TNF-α, IL-1, IL-8, and COX-2, and promotes inflammation and carcinogenesis. In static state, NF-κB in the cells is bound to IκB, inhibitors of κB, and hooked in the cytoplasm. Activation of NF-κB consists of IκB kinase (IKK) activation, IκB phosphorylation and ubiquitinated degradation by 26S proteasomes, and nuclear translocation and DNA binding of free NF-κB, finally promoting target gene expression [43]. Oxidative stress can activate IKK and stimulate nuclear translocation of NF-κB (Figure 2). In the diseased colon tissues of UC patients, NF-κB expression, particularly the p65 (Re1A) and p52/p100 (NF-κB2), is increased, and blockade of NF-κB activity is considered practical treatment of UC [44]. In addition, the activation of p50, c-Rel, and p65 is documented in macrophages in the lamina propria of UC patients [45].

Oxidative stress also activates mitogen-activated protein (MAP) kinase (MAPK) signaling pathways. MAPKs are highly conserved serine/threonine protein kinases functioning in various fundamental cellular processes, such as growth/proliferation, differentiation, motility, and apoptosis/survival, as well as stress response [46]. Conventional MAPKs include the extracellular signal-regulated kinases 1 and 2 (Erk1/2), the c-Jun N-terminal kinases 1–3 (JNK1–3)/stress activated protein kinases (SAPK), the p38 isoforms (p38α, β, γ, and δ), and the Erk5. These MAPKs can be activated by growth factors and mitogens, as well as various stresses. These stimuli activate MAPKK kinases (MAPKKKs) via receptor dependent and independent mechanisms, followed by phosphorylation and activation of a downstream MAPK kinase (MAPKK) and then MAPKs. Activated MAPKs phosphorylate and activate specific target protein kinases, such as RSK, MSK, or MNK to mediate biological processes [47]. The increased ROS can activate ERKs, JNKs, or p38 MAPKs [48, 49]. The exact mechanism by which the ROS activate these kinases is unclear, but a plausible mechanism may be relative to oxidative modifications and resultant activation of the signaling effector proteins and inactivation and/or degradation of MAPK phosphatases (see [50] for more details). Nevertheless, the p38 and JNK signaling activated by ROS is involved in the disease progression of UC [5154]. In UC tissues, p38 MAPK signaling changes are a molecular signature of UC and proportional to the degree of inflammation [55, 56].

2.3. Carbonyl Stress and a Vicious Cell Damage Cycle

A class of carbonyl compounds is called α,β-unsaturated carbonyls, also referred to as electrophilic carbonyls. These include acrolein, glyoxal, methylglyoxal, crotonaldehyde, malondialdehyde, and 4-hydroxynonenal (Table 2). As byproducts, these electrophilic carbonyl compounds are constantly produced during the metabolism of lipids, carbohydrates, amino acids, biogenic amines, vitamins, and steroids, as well as some antitumor agents, such as cyclophosphamide [5763]. Besides endogenous production, daily food consumption may represent the most dangerous exposure of human gastrointestinal (GI) tract to exogenous electrophilic carbonyls which are pervasively present in various beverages and foodstuffs [6466]. For instance, humans are exposed to crotonaldehyde through the consumption of vegetables (1.4–100 µg/kg), fruits (5.4–78 µg/kg), fish (71.4–1000 µg/kg), meat (10–270 µg/kg), and alcoholic beverages, such as wine (300–700 µg/L) and whisky (30–210 µg/L) [66]. Furthermore, methylglyoxal is a constituent of coffee [67, 68], and acetaldehyde is a carcinogenic metabolite of alcohol consumed [69, 70]. Therefore, human GI tract is repeatedly exposed to carbonyl threats, which are important factors of GI inflammatory and neoplastic lesions (Table 3).

Carbonyl compoundsCarbonyl clearance

Acrolein (CH2=CHCHO)
Glyoxal (OHCCHO)
Methylglyoxal (CH3COCHO)
Crotonaldehyde (CH3CH=CHCHO)
Malondialdehyde (OCHCH2CHO)
4-Hydroxynonenal (OCHCH=CHCH(-OH)(CH2)4CH3)
(1) Glutathione-S-transferases (GST) catalyze carbonyl-glutathione conjugation
(2) Aldehyde reductase and aldo-keto reductases (AKRs) catalyze reduction to alcoholic forms
(3) Aldehyde dehydrogenases catalyze oxidation to carbonic acids

Diseases/genotoxicitySpeciesCarbonyl associationReferences

Colitis-associated colorectal neoplasms MiceCoupled with high carbonyl levels, for example, malondialdehyde[19, 153]

Stomach hyperplasia, squamous papilloma, and carcinomaRats2,4-Hexadienal exposure[73]

Precancerous gastritis and gastric cancerHumansHigh serum malondialdehyde levels [154, 155]

Colorectal cancerHumansHigh serum lipid peroxide levels [156]

Colon and gastric cancersHumansAcetaldehyde from alcohol[69, 70]

Colorectal adenocarcinomaHumansHigh protein carbonyl levels[157]

Precancerous colorectal adenopolyps HumansHigh protein carbonyl levels[158]

Colorectal cancer HumansHigh lipid peroxide levels in tissues[159161]

GenotoxicityHumansHigh carbonyl DNA adduct levels in tissues[58, 162, 163]

GenotoxicityCell lines/in vitro studiesProduction of carbonyl DNA adducts [164167]

In organisms, there are three main pathways responsible for elimination of intracellular carbonyls, through which carbonyls are oxidized to carbonic acids, conjugated with glutathione, or reduced to less toxic alcohols. Aldehyde dehydrogenases mediate the oxidative pathway of carbonyls, forming carbonic acids [71, 72]; glutathione-S-transferases (GST) catalyze the conjugation of carbonyls with glutathione [7375]; and aldehyde reductase and aldo-keto reductases (AKRs) are responsible for the reduction of carbonyls to alcohols with NAD(P)H as a coenzyme [7577]. AKR1B10 is the sole carbonyl-detoxifying enzyme with intestine-specific expression identified thus far [78] and plays a critical role in the inflammatory lesions and malignant progression of the colon [19]. Therefore, in normal conditions human consumption or endogenous production of the cytotoxic carbonyls may be subcytotoxic. However, in oxidative stress, excessive ROS oxidize unsaturated fatty acids and produce a large amount of highly reactive α,β-unsaturated carbonyl compounds, that is, lipid peroxides. For instance, 4-hydroxynonenal (HNE) is at 0.1 to 3.0 µM in normal tissues but increases to ~10 µM in the condition of oxidative stress [79]. Carbonyl accumulation due to overproduction and/or impaired clearance, such as AKR1B10 deficiency [19], would lead to carbonyl stress.

Due to their high reactivity, α,β-unsaturated lipid peroxides are highly cytotoxic and genotoxic. They can interact with free amino groups of proteins (e.g., lysine residue), peptides, and amino acids, with sulfhydryl groups of amino acid residues (e.g., cysteine residue), and with histidine and other residues, forming covalently modified adducts [57, 8086]. The covalent modifications could lead to protein dysfunction, resistance to proteolysis, or depolymerization. Protein adducts can also act as special second messengers or autoantigens, promoting macrophage accumulation, retention, and activation, thus increasing ROS generation. Furthermore, carbonyl-induced protein dysfunction may impair mitochondrial respiratory chain reactions and membrane potential, leading to increased ROS production and release into cytosol. Therefore, in inflammatory conditions (i.e., UC), the carbonyl lesions may create a vicious loop with oxidative stress, aggravating cell and tissue damage [19, 87].

3. Oxidative Stress and Carbonyl Lesions in Colitis-Associated Colorectal Cancer

Colorectal cancer (CRC) is the third most common cancer worldwide with mortality ranked within top four [88, 89]. According to International Agency for Research on Cancer of WHO (http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx), about 1.36 million of new CRC cases were diagnosed globally in 2012, accounting for approximately 69,000 deaths. Clinically, there are two main types of CRC, that is, sporadic colorectal cancer (SCC) and hereditary colorectal cancer (HCC). The latter includes familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC). Colorectal adenoma, colorectal nonadenomatous polyposis, and inflammatory bowel disease are precancerous lesions associated with CRC. The UC patients have an increased risk of developing colorectal cancer, so-called colitis-associated colorectal cancer (CAC) [90], and the cancer risk increases exponentially with the duration of disease [9193]. A UC patient with 10 years of disease duration has 10-fold higher CRC risk than the general population.

Etiopathogenesis of CAC is complex. In UC, intestinal epithelial and immune cells produce and secrete a variety of mitogenic cytokines that stimulate cell growth and proliferation. Massive ROS and inflammatory cytokines produced in UC tissues activate multiple signal pathways, such as NF-κB, STAT3, p38 MAPK, and Wnt/β-catenin pathways, which mediate cell proliferation, differentiation, and apoptosis/survival [94]. Finally, DNA damage induced by oxidative and carbonyl stresses plays an essential role in the carcinogenic transformation of the disease. Therefore, malignant progression of UC to CAC is a complicated process and oxidative and carbonyl stresses are key factors in this process.

3.1. Sporadic Colorectal Cancer and Colitis-Associated Colorectal Cancer

CRC is a multistaged, complicated disease associated with multiple oncogene and tumor suppressor gene mutations, such as p53, K-ras, and adenomatous polyposis coli (APC) mutations [95]. In pathogenesis, sporadic CRC often demonstrates an “adenoma-carcinoma” progression, but the CAC experiences a unique sequence of “inflammation-dysplasia-carcinoma” [96]. Patients with UC may experience a long course of dysplasia. Three types of atypical hyperplasia may appear in the carcinogenic process of UC: (1) normal mucosa or mucous membrane with regeneration, also named dysplasia negative type, (2) dysplasia uncertain type, (3) dysplasia positive type. UC patients with high or moderate grade dysplasia are at high risk of developing CAC [97].

CAC also demonstrates a different time line and involvement of gene mutations. In sharp contrast to sporadic CRC, p53 mutation occurs early and is an important step in the progression of CAC. The p53 mutations are often detected in mucosa that is even nondysplastic [98, 99], but APC mutations are present at the late stage of CAC [100103]. K-ras mutation plays a rare role in CAC development [104], but DNA methylation is an early event in UC [105], although less common than in sporadic CRC [106, 107].

3.2. Inflammatory Cytokines and CAC Progression

Inflammatory cytokines produced by intestinal epithelial cells and infiltrated inflammatory cells in UC include IL-1, IL-6, TNF-α, and TGF-β. These cytokines activate mitogenic signaling pathways, stimulate cell proliferation and survival, and thus promote inflammation-associated tumorigenesis. For instance, the plasma level of IL-6 is significantly elevated in patients with IBD, and the increased IL-6 activates STAT3/JAKl signaling, promoting cell proliferation, evolution, and tumorigenic progression [94]; inhibition of JAKl signaling or IL-6 deficiency by targeted disruption diminishes CRC incidence and progression [108, 109].

Tumor necrosis factors (TNF) are proinflammatory cytokines which are produced and secreted mainly by monocyte-macrophages. In this family, TNF-α is an important member that functions in inflammation, immune response, and tumorigenesis. Animal experiments have demonstrated that TNF-α can increase the plasma level of IL-6 [110] and initiate colorectal carcinogenesis mediated by chronic inflammation [111]. To date, TNF-α monoclonal antibody is used for IBD treatment and has demonstrated promising results; this antibody may also be effective in prevention of CAC [112].

TGF-β and family members are secretory signal transduction peptides that regulate cell proliferation and apoptosis. In the normal cells, the major function of TGF-β is to arrest cell division in the early stage of DNA synthesis, induce cell differentiation, or promote apoptosis. Literature reports indicate that mutations in TGF-β signal transduction pathway occur in patients with UC before the formation of colorectal cancer [113]. For example, TGF-βRII mutations have been detected in UC dysplasia and are associated with CAC progression [114].

Finally, inflammatory cytokine IL-1α increases in UC and may be involved in CAC development [115], but compared to other cytokines, the role of IL-1α in the development and progression of CAC is more complicated. IL-1α may promote cancer progression by stimulating angiogenesis [116]; IL-1α may also promote epithelial repair and prevent CAC by inducing the expression of cyclooxygenase 2 (COX-2), a key enzyme of prostaglandin E2 (PGE2) synthesis from arachidonic acid (AA) [117]. PGE2 is a prominent prostaglandin in the intestine; through binding to E prostanoid (EP) receptor, PGE2 mediates intestinal epithelial cell proliferation and apoptosis [118, 119]. This is considered favorable to injury repair and remission of UC. In fact, ulcerogenic response of nonsteroidal anti-inflammatory drugs (NSAIDs) in the intestine is ascribed to inhibition of cyclooxygenases and resultant PGE2 deficiency [120]. In dextran sodium sulfate- (DSS-) induced colitis, COX-2/PGE2 promotes epithelial cell proliferation; inhibition of COX-2 decreases epithelial proliferation, exacerbates colitis, and prolongs injury phase, thus promoting intestinal injury and dysplasia [121123]. Therefore, evaluation of IL-1α in CAC development and progression needs to be more cautious.

3.3. Oxidative DNA Damage in CAC Progression

DNA mutations and resultant protooncogene activation and/or tumor suppressor gene inactivation are a hallmark of cell carcinogenesis, which reprograms cell growth, division, and gene transcription. The high risk of UC patients to develop colorectal cancer is essentially attributed to the increased DNA damage induced by inflammatory oxidative stress and carbonyl lesions. DNA is a ready target of active oxygen free radicals, leading to oxidative DNA damage. Through abstractions and addition reactions, highly reactive hydroxyl radicals react with the heterocyclic DNA bases and sugar moiety, producing carbon-centered sugar radicals and OH- or H-adduct radicals of heterocyclic bases [124]. Further reactions of these radicals yield numerous effects, such as 8,5′-cyclopurine-2′-deoxynucleosides, tandem lesions, clustered sites, and DNA-protein cross-links [124, 125]. Among types of oxidative DNA damage induced by ROS, 8-hydroxy-2′-deoxyguanosine (8-OHdG) or 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) is a predominant form and a valuable biomarker widely used for endogenous oxidative damage to DNA (Figure 1). For instance, the urinary 8-OHdG is used as a biomarker for risk assessment of cancers and degenerative diseases [126, 127].

GC to TA transversion is a major type of DNA mutations resulting from 8-OHdG adducts [128]; two common target genes of the 8-OHdG damage are Ras and p53, leading to activation of the protooncogene Ras and inactivation of p53 tumor suppressor, driving tumorigenesis [129, 130]. ROS also cause DNA methylation, single- and double-strand breaks, and shortening of telomeres. DNA methylation is an early event in the progression of UC to CAC [105], but less common than in sporadic CRC [106, 107]. Oppositely, DNA breaks and telomere shortening occur more often in the UC-associated tumorigenesis [131, 132]. The telomere shortening induced by ROS could induce chromosome instability, leading to chromosomal loss, heteroploid, amplification, and translocation, driving tumorigenesis [133, 134].

3.4. Carbonyl DNA Damage in CAC Progression

Carbonyl stress derived from lipid peroxidation is also an important DNA damage factor in UC. Electrophilic carbonyls can readily react with DNA forming covalently modified DNA adducts (Figure 1). The DNA adducts can block DNA semiconservative replication performed by DNA polymerases or arrest transcription driven by RNA polymerases [58, 135137]. DNA adducts can also cause miscoding and induce DNA breaks [58, 137139]. For instance, malondialdehyde (MDA) can react with deoxyguanosine in DNA to form an exocyclic adduct, pyrimido[1,2-alpha]purin-10(3H)-one (M1G), which is mutagenic by resulting in frameshift mutations and base pair substitutions [140]. The 4-HNE-dG polymer derived from 4-hydroxynonenal can lead to GC to TA transversion at codon 249 of p53 gene, driving UC progression to CAC [141, 142].

Of note, DNA breaks induced by carbonyl compounds may activate cellular DNA damage response (DDR), inducing cell cycle arrest for DNA repair or apoptosis (Figure 3). In this DDR process, ATM/ATR functions as a sensor of DNA breaks, and p53 acts as a key mediator [143, 144]. Sensing the DNA double-strand breaks, ATM/ATR is activated by phosphorylation, which reaches the peak within 30 minutes [145]. The activated ATM/ATR phosphorylates p53 at Ser15 and/or Chk1/Chk2 at Ser345, and Chk1/Chk2 further phosphorylate p53 at Ser20 [146]. Activated p53 triggers cell cycle arrest for DNA damage repair or apoptosis to eliminate cells with severe DNA damage through selective activation of target gene expression, such as apoptotic genes Fas-R, Bax, Puma, and Noxa or cell cycle monitoring and DNA repair genes and p53R2 [147]. Therefore, DDR is considered a barrier of carcinogenesis, and mutations of genes in this pathway are carcinogenic. In fact, p53 mutation is an early event in CAC and occurs even in noncancerous UC tissues [148, 149].

4. Conclusion and Perspective

Early in 1863, a German pathologist Virchow proposed that tumor might be derived from chronic inflammation tissues; in 2009, Hanahan and Weinberg proposed tumor-related inflammation as the seventh hallmark of cancer. To date, the role of chronic inflammation in cancer development and progression has become an important research focus in tumor microenvironment. In UC, the pathogenesis of CAC is a classical path of nonresolving inflammatory progression to cancer, featured with a unique sequence of “inflammation-dysplasia-carcinoma.” Oxidative stress and secondary carbonyl lesions are key factors in the development and progression of UC and CAC; the ROS take an important part in multiple stages of initiation, promotion, and progression of UC and CAC and the secondary carbonyl lesions play an exaggerating role both in oxidative stress itself and in progression of UC and CAC (Figure 4).

To date, antioxidant prevention and treatment have been investigated in experimental animals of colitis and in clinical patients of UC. In animals, antioxidant G. biloba extract (EGb 761) showed effectiveness in prevention and treatment of DSS-induced colitis in mice [150], and the Zingiber officinale extract demonstrated efficacy in modulating extent and severity of colitis in rats [151]. In humans, consumptions of antioxidant food, such as blueberries, cherries, tomatoes, squashes, and bell peppers have been suggested as supplementary treatment of active UC and prevention of reactivation. More impressively, a clinical trial of rectal d-alpha tocopherol, a powerful vitamin E antioxidant, has shown that “all 14 patients responded clinically to the therapy and remission was induced in 9 of them (64%)”; no adverse events were reported and no patients were hospitalized for “worsened disease activity” [152]. These preclinical and clinical approaches suggest that antioxidant treatment may be a novel mode of UC management and prevention of malignant progression. Further studies are warranted.


AIF:Apoptosis inducing factor
AKR1B10:Aldo-keto reductase 1B10
APC:Adenomatous polyposis coli
CAC:Colitis-associated colorectal cancer
COX-2:Cyclooxygenase 2
CRC:Colorectal cancer
DSS:Dextran sodium sulfate
GSH-PX:Glutathione peroxidase
IBD:Inflammatory bowel disease
NOX:Nicotinamide adenine dinucleotide phosphate oxidase
OS:Oxidative stress
Raf:Root abundant factor
ROS:Reactive oxygen species
SCC:Sporadic colorectal cancer
SOD:Superoxide dismutase
TGF-:Transforming growth factor
TNF-:Tumor necrosis factor
UC:Ulcerative stress.

Conflict of Interests

Authors declare no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Zhiqi Wang wrote draft. Sai Li draw figures. Duan-Fang Liao, Yu Cao, Xuefei Tian, and Rong Zeng contributed to literature search and discussion. Deliang Cao revised the paper. All authors read and approved the final version of this paper.


This work was supported in part by Hunan Engineering Center for Rapid Test and Removal of Toxic and Harmful Substances in Chinese Medicine (201303 for Zhiqi Wang) and by National Natural Science Foundation of China (81503492 for Zhiqi Wang; 81272918 and 81472465 for Deliang Cao).


  1. B. D'Autréaux and M. B. Toledano, “ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis,” Nature Reviews Molecular Cell Biology, vol. 8, no. 10, pp. 813–824, 2007. View at: Publisher Site | Google Scholar
  2. G. P. Lambert, “Stress-induced gastrointestinal barrier dysfunction and its inflammatory effects,” Journal of animal science, vol. 87, no. 14, pp. E101–E108, 2009. View at: Publisher Site | Google Scholar
  3. S. M. Karp and T. R. Koch, “Oxidative stress and antioxidants in inflammatory bowel disease,” Disease-A-Month, vol. 52, no. 5, pp. 199–207, 2006. View at: Publisher Site | Google Scholar
  4. K. H. Cheeseman and T. F. Slater, “An introduction to free radical biochemistry,” British Medical Bulletin, vol. 49, no. 3, pp. 481–493, 1993. View at: Google Scholar
  5. M. Geiszt, K. Lekstrom, S. Brenner et al., “NAD(P)H oxidase 1, a product of differentiated colon epithelial cells, can partially replace glycoprotein 91phox in the regulated production of superoxide by phagocytes,” Journal of Immunology, vol. 171, no. 1, pp. 299–306, 2003. View at: Publisher Site | Google Scholar
  6. S. Dutta and K. Rittinger, “Regulation of NOXO1 activity through reversible interactions with p22phox and NOXA1,” PLoS ONE, vol. 5, no. 5, Article ID e10478, 2010. View at: Publisher Site | Google Scholar
  7. D. C. Baumgart and A. U. Dignass, “Intestinal barrier function,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 5, no. 6, pp. 685–694, 2002. View at: Publisher Site | Google Scholar
  8. H. Okur, M. Küçükaydin, K. Köse, O. Kontaş, P. Doǧan, and A. Kazez, “Hypoxia-induced necrotizing enterocolitis in the immature rat: the role of lipid peroxidation and management by vitamin E,” Journal of Pediatric Surgery, vol. 30, no. 10, pp. 1416–1419, 1995. View at: Publisher Site | Google Scholar
  9. K. L. Chan, C. W. C. Hui, K. W. Chan et al., “Revisiting ischemia and reperfusion injury as a possible cause of necrotizing enterocolitis: role of nitric oxide and superoxide dismutase,” Journal of Pediatric Surgery, vol. 37, no. 6, pp. 828–834, 2002. View at: Publisher Site | Google Scholar
  10. S. Danese and C. Fiocchi, “Ulcerative colitis,” The New England Journal of Medicine, vol. 365, no. 18, pp. 1713–1725, 2011. View at: Publisher Site | Google Scholar
  11. P. M. Irving, “Recent advances in the management of inflammatory bowel disease,” Clinical Medicine, vol. 9, no. 6, pp. 605–608, 2009. View at: Google Scholar
  12. J. Meier and A. Sturm, “Current treatment of ulcerative colitis,” World Journal of Gastroenterology, vol. 17, no. 27, pp. 3204–3212, 2011. View at: Publisher Site | Google Scholar
  13. U. Weiss, “Inflammation,” Nature, vol. 454, no. 7203, p. 427, 2008. View at: Publisher Site | Google Scholar
  14. A. Bitton, M. A. Peppercorn, D. A. Antonioli et al., “Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis,” Gastroenterology, vol. 120, no. 1, pp. 13–20, 2001. View at: Publisher Site | Google Scholar
  15. N. Oshitani, Y. Sawa, J. Hara et al., “Functional and phenotypical activation of leucocytes in inflamed human colonic mucosa,” Journal of Gastroenterology and Hepatology, vol. 12, no. 12, pp. 809–814, 1997. View at: Publisher Site | Google Scholar
  16. D. K. Podolsky, “Inflammatory bowel disease,” The New England Journal of Medicine, vol. 347, no. 6, pp. 417–429, 2002. View at: Publisher Site | Google Scholar
  17. K. A. Head and J. J. S. Jurenka, “Inflammatory bowel disease part I: ulcerative colitis—pathophysiology and conventional and alternative treatment options,” Alternative Medicine Review, vol. 8, no. 3, pp. 247–283, 2003. View at: Google Scholar
  18. J. Satsangi, M. Parkes, E. Louis et al., “Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12,” Nature Genetics, vol. 14, no. 2, pp. 199–202, 1996. View at: Publisher Site | Google Scholar
  19. Y. Shen, J. Ma, R. Yan et al., “Impaired Self-Renewal and Increased Colitis and Dysplastic Lesions in Colonic Mucosa of AKR1B8-Deficient Mice,” Clinical Cancer Research, vol. 21, no. 6, pp. 1466–1476, 2015. View at: Publisher Site | Google Scholar
  20. H. Zhu and Y. R. Li, “Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence,” Experimental Biology and Medicine, vol. 237, no. 5, pp. 474–480, 2012. View at: Publisher Site | Google Scholar
  21. P. Magliano, M. Flipphi, B. A. Arpat, S. Delessert, and Y. Poirier, “Contributions of the peroxisome and β-oxidation cycle to biotin synthesis in fungi,” The Journal of Biological Chemistry, vol. 286, no. 49, pp. 42133–42140, 2011. View at: Publisher Site | Google Scholar
  22. W. Gehrmann and M. Elsner, “A specific fluorescence probe for hydrogen peroxide detection in peroxisomes,” Free Radical Research, vol. 45, no. 5, pp. 501–506, 2011. View at: Publisher Site | Google Scholar
  23. M. Fransen, M. Nordgren, B. Wang, and O. Apanasets, “Role of peroxisomes in ROS/RNS-metabolism: implications for human disease,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1822, no. 9, pp. 1363–1373, 2012. View at: Publisher Site | Google Scholar
  24. T. D. Engerson, G. McKelvey, D. B. Rhyne, E. B. Boggio, S. J. Snyder, and H. P. Jones, “Conversion of xanthine dehydrogenase to oxidase in ischemic rat tissues,” Journal of Clinical Investigation, vol. 79, no. 6, pp. 1564–1570, 1987. View at: Publisher Site | Google Scholar
  25. S. Angermuller and H. D. Fahimi, “Ultrastructural cytochemical localization of uricase in peroxisomes of rat liver,” Journal of Histochemistry and Cytochemistry, vol. 34, no. 2, pp. 159–165, 1986. View at: Publisher Site | Google Scholar
  26. P. Cerutti, R. Ghosh, Y. Oya, and P. Amstad, “The role of the cellular antioxidant defense in oxidant carcinogenesis,” Environmental Health Perspectives, vol. 102, supplement 10, pp. 123–129, 1994. View at: Publisher Site | Google Scholar
  27. A. Rahal, A. Kumar, V. Singh et al., “Oxidative stress, prooxidants, and antioxidants: the interplay,” BioMed Research International, vol. 2014, Article ID 761264, 19 pages, 2014. View at: Publisher Site | Google Scholar
  28. J. Lee, E.-R. Hahm, and S. V. Singh, “Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells,” Carcinogenesis, vol. 31, no. 11, pp. 1991–1998, 2010. View at: Publisher Site | Google Scholar
  29. C. A. de La Lastra and I. Villegas, “Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications,” Biochemical Society Transactions, vol. 35, no. 5, pp. 1156–1160, 2007. View at: Publisher Site | Google Scholar
  30. P. Brookes and V. M. Darley-Usmar, “Hypothesis: the mitochondrial NO() signaling pathway, and the transduction of nitrosative to oxidative cell signals: an alternative function for cytochrome C oxidase,” Free Radical Biology and Medicine, vol. 32, pp. 370–374, 2002. View at: Google Scholar
  31. Z. Cai and L. J. Yan, “Protein oxidative modifications: beneficial roles in disease and health,” Journal of Biochemical and Pharmacological Research, vol. 1, no. 1, pp. 15–26, 2013. View at: Google Scholar
  32. G. R. Hodges and K. U. Ingold, “Superoxide, amine buffers and tetranitromethane: a novel free radical chain reaction,” Free Radical Research, vol. 33, no. 5, pp. 547–550, 2000. View at: Publisher Site | Google Scholar
  33. R. M. Sargis and P. V. Subbaiah, “Protection of membrane cholesterol by sphingomyelin against free radical-mediated oxidation,” Free Radical Biology and Medicine, vol. 40, no. 12, pp. 2092–2102, 2006. View at: Publisher Site | Google Scholar
  34. I. Juránek and Š. Bezek, “Controversy of free radical hypothesis: reactive oxygen species—cause or consequence of tissue injury,” General Physiology and Biophysics, vol. 24, no. 3, pp. 263–278, 2005. View at: Google Scholar
  35. V. Calabrese, R. Lodi, C. Tonon et al., “Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia,” Journal of the Neurological Sciences, vol. 233, no. 1-2, pp. 145–162, 2005. View at: Publisher Site | Google Scholar
  36. S. Wasiak, R. Zunino, and H. M. McBride, “Bax/Bak promote sumoylation of DRP1 and its stable association with mitochondria during apoptotic cell death,” The Journal of Cell Biology, vol. 177, no. 3, pp. 439–450, 2007. View at: Publisher Site | Google Scholar
  37. G. Paradies, G. Petrosillo, V. Paradies, and F. M. Ruggiero, “Role of cardiolipin peroxidation and Ca2+ in mitochondrial dysfunction and disease,” Cell Calcium, vol. 45, no. 6, pp. 643–650, 2009. View at: Publisher Site | Google Scholar
  38. P. P. Tak and G. S. Firestein, “NF-kappaB: a key role in inflammatory diseases,” The Journal of Clinical Investigation, vol. 107, no. 1, pp. 7–11, 2001. View at: Publisher Site | Google Scholar
  39. T. Karrasch and C. Jobin, “NF-κB and the intestine: friend or foe?” Inflammatory Bowel Diseases, vol. 14, no. 1, pp. 114–124, 2008. View at: Publisher Site | Google Scholar
  40. E. P. Cummins, G. A. Doherty, and C. T. Taylor, “Hydroxylases as therapeutic targets in inflammatory bowel disease,” Laboratory Investigation, vol. 93, no. 4, pp. 378–383, 2013. View at: Publisher Site | Google Scholar
  41. K. Wang, S. I. Grivennikov, and M. Karin, “Implications of anti-cytokine therapy in colorectal cancer and autoimmune diseases,” Annals of the Rheumatic Diseases, vol. 72, supplement 2, pp. ii100–ii103, 2013. View at: Publisher Site | Google Scholar
  42. R. Schreck, K. Albermann, and P. A. Baeuerle, “Nuclear factor kb: an oxidative stress-responsive transcription factor of eukaryotic cells (a review),” Free Radical Research, vol. 17, no. 4, pp. 221–237, 1992. View at: Publisher Site | Google Scholar
  43. C. Pantano, N. L. Reynaert, A. van der Vliet, and Y. M. W. Janssen-Heininger, “Redox-sensitive kinases of the nuclear factor-κB signaling pathway,” Antioxidants and Redox Signaling, vol. 8, no. 9-10, pp. 1791–1806, 2006. View at: Publisher Site | Google Scholar
  44. A. S. Baldwin Jr., “The NF-κB and IκB proteins: new discoveries and insights,” Annual Review of Immunology, vol. 14, pp. 649–683, 1996. View at: Publisher Site | Google Scholar
  45. A. Kaser, S. Zeissig, and R. S. Blumberg, “Inflammatory bowel disease,” Annual Review of Immunology, vol. 28, pp. 573–621, 2010. View at: Publisher Site | Google Scholar
  46. Y. Topcu-Tarladacalisir, M. Akpolat, Y. H. Uz et al., “Effects of curcumin on apoptosis and oxidoinflammatory regulation in a rat model of acetic acid-induced colitis: the roles of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase,” Journal of Medicinal Food, vol. 16, no. 4, pp. 296–305, 2013. View at: Publisher Site | Google Scholar
  47. A. Higa and E. Chevet, “Redox signaling loops in the unfolded protein response,” Cellular Signalling, vol. 24, no. 8, pp. 1548–1555, 2012. View at: Publisher Site | Google Scholar
  48. G. H. Waetzig, D. Seegert, S. Nikolaus, P. Rosenstiel, N. Sfikas, and S. Schreiber, “Differential activity and expression of mitogen-activated protein kinases in inflammatory bowel disease,” Gastroenterology, vol. 120, no. 5, p. A522, 2001. View at: Google Scholar
  49. G. H. Waetzig, D. Seegert, P. Rosenstiel, S. Nikolaus, and S. Schreiber, “p38 mitogen-activated protein kinase is activated and linked to TNF-α signaling in inflammatory bowel disease,” Journal of Immunology, vol. 168, no. 10, pp. 5342–5351, 2002. View at: Publisher Site | Google Scholar
  50. Y. Son, Y. Cheong, N. Kim, H. Chung, D. G. Kang, and H. Pae, “Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways?” Journal of Signal Transduction, vol. 2011, Article ID 792639, 6 pages, 2011. View at: Publisher Site | Google Scholar
  51. E. Hollenbach, M. Neumann, M. Vieth, A. Roessner, P. Malfertheiner, and M. Naumann, “Inhibition of p38 MAP kinase- and RICK/NF-κB-signaling suppresses inflammatory bowel disease,” The FASEB Journal, vol. 18, no. 13, pp. 1550–1552, 2004. View at: Publisher Site | Google Scholar
  52. E. Hollenbach, M. Vieth, A. Roessner, M. Neumann, P. Malfertheiner, and M. Naumann, “Inhibition of RICK/nuclear factor-κB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease,” Journal of Biological Chemistry, vol. 280, no. 15, pp. 14981–14988, 2005. View at: Publisher Site | Google Scholar
  53. J. Wei and J. Feng, “Signaling pathways associated with inflammatory bowel disease,” Recent Patents on Inflammation and Allergy Drug Discovery, vol. 4, no. 2, pp. 105–117, 2010. View at: Publisher Site | Google Scholar
  54. Y. J. Feng and Y. Y. Li, “The role of p38 mitogen-activated protein kinase in the pathogenesis of inflammatory bowel disease,” Journal of Digestive Diseases, vol. 12, no. 5, pp. 327–332, 2011. View at: Publisher Site | Google Scholar
  55. D. Hommes, B. van den Blink, T. Plasse et al., “Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease,” Gastroenterology, vol. 122, no. 1, pp. 7–14, 2002. View at: Publisher Site | Google Scholar
  56. X. Zhao, B. Kang, C. Lu et al., “Evaluation of P38 MAPK pathway as a molecular signature in ulcerative colitis,” Journal of Proteome Research, vol. 10, no. 5, pp. 2216–2225, 2011. View at: Publisher Site | Google Scholar
  57. V. V. Davydov, N. M. Dobaeva, and A. I. Bozhkov, “Possible role of alteration of aldehyde's scavenger enzymes during aging,” Experimental Gerontology, vol. 39, no. 1, pp. 11–16, 2004. View at: Publisher Site | Google Scholar
  58. R. De Bont and N. van Larebeke, “Endogenous DNA damage in humans: a review of quantitative data,” Mutagenesis, vol. 19, no. 3, pp. 169–185, 2004. View at: Publisher Site | Google Scholar
  59. S. K. Jain, N. Mohandas, M. R. Clark, and S. B. Shohet, “The effect of malonyldialdehyde, a product of lipid peroxidation, on the deformability, dehydration and 51Cr-survival of erythrocytes,” British Journal of Haematology, vol. 53, no. 2, pp. 247–255, 1983. View at: Publisher Site | Google Scholar
  60. O. Ullrich, W. Henke, T. Grune, and W. G. Siems, “The effect of the lipid peroxidation product 4-hydroxynonenal and of its metabolite 4-hydroxynonenoic acid on respiration of rat kidney cortex mitochondria,” Free Radical Research, vol. 24, no. 6, pp. 421–427, 1996. View at: Publisher Site | Google Scholar
  61. S. Choudhary, T. Xiao, S. Srivastava et al., “Toxicity and detoxification of lipid-derived aldehydes in cultured retinal pigmented epithelial cells,” Toxicology and Applied Pharmacology, vol. 204, no. 2, pp. 122–134, 2005. View at: Publisher Site | Google Scholar
  62. K. Berhane, M. Widersten, Å. Engström, J. W. Kozarich, and B. Mannervik, “Detoxication of base propenals and other α,β-unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 4, pp. 1480–1484, 1994. View at: Publisher Site | Google Scholar
  63. C. E. Vaca, J. A. Nilsson, J.-L. Fang, and R. C. Grafström, “Formation of DNA adducts in human buccal epithelial cells exposed to acetaldehyde and methylglyoxal in vitro,” Chemico-Biological Interactions, vol. 108, no. 3, pp. 197–208, 1998. View at: Publisher Site | Google Scholar
  64. B. N. Ames, “Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases,” Science, vol. 221, no. 4617, pp. 1256–1264, 1983. View at: Publisher Site | Google Scholar
  65. K. Fujioka and T. Shibamoto, “Formation of genotoxic dicarbonyl compounds in dietary oils upon oxidation,” Lipids, vol. 39, no. 5, pp. 481–486, 2004. View at: Publisher Site | Google Scholar
  66. B. D. Schuler and E. Eder, “Development of a 32P-postlabelling method for the detection of 1,N2-propanodeoxyguanosine adducts of crotonaldehyde in vivo,” Archives of Toxicology, vol. 74, no. 7, pp. 404–414, 2000. View at: Publisher Site | Google Scholar
  67. H. Kasai, K. Kumeno, Z. Yamaizumi et al., “Mutagenicity of methylglyoxal in coffee,” Gann, vol. 73, no. 5, pp. 681–683, 1982. View at: Google Scholar
  68. H. Nukaya, T. Iwami, H. Ishida et al., “N-2 Acetylation of 2′-deoxyguanosine by coffee mutagens, methylglyoxal and hydrogen peroxide,” Mutation Research Letters, vol. 245, no. 4, pp. 251–257, 1990. View at: Publisher Site | Google Scholar
  69. N. Homann, J. Tillonen, and M. Salaspuro, “Microbially produced acetaldehyde from ethanol may increase the risk of colon cancer via folate deficiency,” International Journal of Cancer, vol. 86, no. 2, pp. 169–173, 2000. View at: Publisher Site | Google Scholar
  70. M. P. Salaspuro, “Alcohol consumption and cancer of the gastrointestinal tract,” Bailliere's Best Practice and Research in Clinical Gastroenterology, vol. 17, no. 4, pp. 679–694, 2003. View at: Publisher Site | Google Scholar
  71. V. Vasiliou, A. Pappa, and D. R. Petersen, “Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism,” Chemico-Biological Interactions, vol. 129, no. 1-2, pp. 1–19, 2000. View at: Publisher Site | Google Scholar
  72. N. E. Sládek, “Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact,” Journal of Biochemical and Molecular Toxicology, vol. 17, no. 1, pp. 7–23, 2003. View at: Publisher Site | Google Scholar
  73. A. Nyska, C. R. Moomaw, L. Lomnitski, and P. C. Chan, “Glutathione S-transferase Pi expression in forestomach carcinogenesis process induced by gavage-administered 2,4-hexadienal in the F344 rat,” Archives of Toxicology, vol. 75, no. 10, pp. 618–624, 2001. View at: Publisher Site | Google Scholar
  74. B. F. Coles and F. F. Kadlubar, “Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs?” BioFactors, vol. 17, no. 1–4, pp. 115–130, 2003. View at: Publisher Site | Google Scholar
  75. S. Srivastava, A. Chandra, A. Bhatnagar, S. K. Srivastava, and N. H. Ansari, “Lipid peroxidation product, 4-hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase,” Biochemical and Biophysical Research Communications, vol. 217, no. 3, pp. 741–746, 1995. View at: Publisher Site | Google Scholar
  76. L. Zhong, Z. Liu, R. Yan et al., “Aldo-keto reductase family 1 B10 protein detoxifies dietary and lipid-derived alpha, beta-unsaturated carbonyls at physiological levels,” Biochemical and Biophysical Research Communications, vol. 387, no. 2, pp. 245–250, 2009. View at: Publisher Site | Google Scholar
  77. Y. Shen, L. Zhong, S. Johnson, and D. Cao, “Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophilic carbonyl compounds,” Chemico-Biological Interactions, vol. 191, no. 1–3, pp. 192–198, 2011. View at: Publisher Site | Google Scholar
  78. D. Cao, S. T. Fan, and S. S. M. Chung, “Identification and characterization of a novel human aldose reductase- like gene,” The Journal of Biological Chemistry, vol. 273, no. 19, pp. 11429–11435, 1998. View at: Publisher Site | Google Scholar
  79. H. Esterbauer, P. Eckl, and A. Ortner, “Possible mutagens derived from lipids and lipid precursors,” Mutation Research/Reviews in Genetic Toxicology, vol. 238, no. 3, pp. 223–233, 1990. View at: Google Scholar
  80. H. Li, J. Wang, B. S. Kaphalia, G. A. S. Ansari, and M. F. Khan, “Quantitation of acrolein-protein adducts: potential biomarker of acrolein exposure,” Journal of Toxicology and Environmental Health Part: A, vol. 67, no. 6, pp. 513–524, 2004. View at: Publisher Site | Google Scholar
  81. M. Hashimoto, T. Sibata, H. Wasada, S. Toyokuni, and K. Uchida, “Structural basis of protein-bound endogenous aldehydes. Chemical and immunochemical characterizations of configurational isomers of a 4-hydroxy-2-nonenal-histidine adduct,” The Journal of Biological Chemistry, vol. 278, no. 7, pp. 5044–5051, 2003. View at: Publisher Site | Google Scholar
  82. K. Uchida and E. R. Stadtman, “Modification of histidine residues in proteins by reaction with 4- hydroxynonenal,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 10, pp. 4544–4548, 1992. View at: Publisher Site | Google Scholar
  83. J. G. Alvarez and B. T. Storey, “Assessment of cell damage caused by spontaneous lipid peroxidation in rabbit spermatozoa,” Biology of Reproduction, vol. 30, no. 2, pp. 323–331, 1984. View at: Publisher Site | Google Scholar
  84. K. Okada, C. Wangpoengtrakul, T. Osawa, S. Toyokuni, K. Tanaka, and K. Uchida, “4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules,” The Journal of Biological Chemistry, vol. 274, no. 34, pp. 23787–23793, 1999. View at: Publisher Site | Google Scholar
  85. K. Uchida and E. R. Stadtman, “Selective cleavage of thioether linkage in proteins modified with 4-hydroxynonenal,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 12, pp. 5611–5615, 1992. View at: Publisher Site | Google Scholar
  86. S. Hauptlorenz, H. Esterbauer, W. Moll, R. Pümpel, E. Schauenstein, and B. Puschendorf, “Effects of the lipidperoxidation product 4-hydroxynonenal and related aldehydes on proliferation and viability of cultured ehrlich ascites tumor cells,” Biochemical Pharmacology, vol. 34, no. 21, pp. 3803–3809, 1985. View at: Publisher Site | Google Scholar
  87. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at: Publisher Site | Google Scholar
  88. D. Cunningham, W. Atkin, H.-J. Lenz et al., “Colorectal cancer,” The Lancet, vol. 375, no. 9719, pp. 1030–1047, 2010. View at: Publisher Site | Google Scholar
  89. N. Chawla, E. N. Butler, J. Lund, J. L. Warren, L. C. Harlan, and K. R. Yabroff, “Patterns of colorectal cancer care in Europe, Australia, and New Zealand,” Journal of the National Cancer Institute—Monographs, vol. 2013, no. 46, pp. 36–61, 2013. View at: Publisher Site | Google Scholar
  90. D. N. Seril, J. Liao, G.-Y. Yang, and C. S. Yang, “Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models,” Carcinogenesis, vol. 24, no. 3, pp. 353–362, 2003. View at: Publisher Site | Google Scholar
  91. S. Danese, A. Malesci, and S. Vetrano, “Colitis-associated cancer: the dark side of inflammatory bowel disease,” Gut, vol. 60, no. 12, pp. 1609–1610, 2011. View at: Publisher Site | Google Scholar
  92. R. H. Collins Jr., M. Feldman, and J. S. Fordtran, “Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review,” The New England Journal of Medicine, vol. 316, no. 26, pp. 1654–1658, 1987. View at: Publisher Site | Google Scholar
  93. A. Ekbom, C. Helmick, M. Zack, and H.-O. Adami, “Ulcerative colitis and colorectal cancer. A population-based study,” The New England Journal of Medicine, vol. 323, no. 18, pp. 1228–1233, 1990. View at: Publisher Site | Google Scholar
  94. S. Grivennikov, E. Karin, J. Terzic et al., “IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer,” Cancer Cell, vol. 15, no. 2, pp. 103–113, 2009. View at: Publisher Site | Google Scholar
  95. S. Aretz, H. F. A. Vasen, and S. Olschwang, “Clinical utility gene card for: familial adenomatous polyposis (FAP) and attenuated FAP (AFAP),” European Journal of Human Genetics, vol. 19, no. 7, 2011. View at: Publisher Site | Google Scholar
  96. S. H. Itzkowitz and X. Yio, “Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 287, no. 1, pp. G7–G17, 2004. View at: Publisher Site | Google Scholar
  97. L. Lakatos, G. Mester, Z. Erdelyi et al., “Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study,” Inflammatory Bowel Diseases, vol. 12, no. 3, pp. 205–211, 2006. View at: Publisher Site | Google Scholar
  98. J. K. Triantafillidis, G. Nasioulas, and P. A. Kosmidis, “Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies,” Anticancer Research, vol. 29, no. 7, pp. 2727–2737, 2009. View at: Google Scholar
  99. T. A. Ullman and S. H. Itzkowitz, “Intestinal inflammation and cancer,” Gastroenterology, vol. 140, no. 6, pp. 1807–1816, 2011. View at: Publisher Site | Google Scholar
  100. D. E. Aust, J. P. Terdiman, R. F. Willenbucher et al., “The APC/β-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis,” Cancer, vol. 94, no. 5, pp. 1421–1427, 2002. View at: Publisher Site | Google Scholar
  101. J. You, A. V. Nguyen, C. G. Albers, F. Lin, and R. F. Holcombe, “Wnt pathway-related gene expression in inflammatory bowel disease,” Digestive Diseases and Sciences, vol. 53, no. 4, pp. 1013–1019, 2008. View at: Publisher Site | Google Scholar
  102. D. C. M. Rapozo, A. B. Grinmann, A. T. P. Carvalho et al., “Analysis of mutations in TP53, APC, K-ras, and DCC genes in the non-dysplastic mucosa of patients with inflammatory bowel disease,” International Journal of Colorectal Disease, vol. 24, no. 10, pp. 1141–1148, 2009. View at: Publisher Site | Google Scholar
  103. L. Tarmin, J. Yin, N. Harpaz et al., “Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms,” Cancer Research, vol. 55, no. 10, pp. 2035–2038, 1995. View at: Google Scholar
  104. S. A. Azer, “Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development,” European Journal of Gastroenterology and Hepatology, vol. 25, no. 3, pp. 271–281, 2013. View at: Publisher Site | Google Scholar
  105. F.-Y. Wang, T. Arisawa, T. Tahara et al., “Aberrant DNA methylation in ulcerative colitis without neoplasia,” Hepato-Gastroenterology, vol. 55, no. 81, pp. 62–65, 2008. View at: Google Scholar
  106. K. Konishi, L. Shen, S. Wang, S. J. Meltzer, N. Harpaz, and J.-P. J. Issa, “Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias,” Gastroenterology, vol. 132, no. 4, pp. 1254–1260, 2007. View at: Publisher Site | Google Scholar
  107. J. A. Sanchez, K. L. Dejulius, M. Bronner, J. M. Church, and M. F. Kalady, “Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer,” Inflammatory Bowel Diseases, vol. 17, no. 9, pp. 1966–1970, 2011. View at: Publisher Site | Google Scholar
  108. W.-W. Lin and M. Karin, “A cytokine-mediated link between innate immunity, inflammation, and cancer,” The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1175–1183, 2007. View at: Publisher Site | Google Scholar
  109. C. Becker, M. C. Fantini, C. Schramm et al., “TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling,” Immunity, vol. 21, no. 4, pp. 491–501, 2004. View at: Publisher Site | Google Scholar
  110. G. M. Anderson, M. T. Nakada, and M. DeWitte, “Tumor necrosis factor-α in the pathogenesis and treatment of cancer,” Current Opinion in Pharmacology, vol. 4, no. 4, pp. 314–320, 2004. View at: Publisher Site | Google Scholar
  111. B. K. Popivanova, K. Kitamura, Y. Wu et al., “Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis,” Journal of Clinical Investigation, vol. 118, no. 2, pp. 560–570, 2008. View at: Publisher Site | Google Scholar
  112. M. Allez, S. Vermeire, N. Mozziconacci et al., “The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies,” Alimentary Pharmacology and Therapeutics, vol. 31, no. 1, pp. 92–101, 2010. View at: Publisher Site | Google Scholar
  113. S. J. Engle, I. Ormsby, S. Pawlowski et al., “Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice,” Cancer Research, vol. 62, no. 22, pp. 6362–6366, 2002. View at: Google Scholar
  114. R. F. Souza, J. Lei, J. Yin et al., “A transforming growth factor beta 1 receptor type II mutation in ulcerative colitis-associated neoplasms,” Gastroenterology, vol. 112, no. 1, pp. 40–45, 1997. View at: Publisher Site | Google Scholar
  115. H. Iwagaki, A. Hizuta, and N. Tanaka, “Interleukin-1 receptor antagonists and other markers in colorectal cancer patients,” Scandinavian Journal of Gastroenterology, vol. 32, no. 6, pp. 577–581, 1997. View at: Publisher Site | Google Scholar
  116. Y. Matsuo, H. Sawai, J. Ma et al., “IL-1α secreted by colon cancer cells enhances angiogenesis: the relationship between IL-1α release and tumor cells' potential for liver metastasis,” Journal of Surgical Oncology, vol. 99, no. 6, pp. 361–367, 2009. View at: Publisher Site | Google Scholar
  117. J. F. Di Mari, J. I. Saada, R. C. Mifflin, J. D. Valentich, and D. W. Powell, “HETEs enhance IL-1-mediated COX-2 expression via augmentation of message stability in human colonic myofibroblasts,” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 293, no. 4, pp. G719–G728, 2007. View at: Publisher Site | Google Scholar
  118. W. F. Stenson, “Prostaglandins and epithelial response to injury,” Current Opinion in Gastroenterology, vol. 23, no. 2, pp. 107–110, 2007. View at: Publisher Site | Google Scholar
  119. L. T. Hult, C. R. Kleiveland, K. Fosnes, M. Jacobsen, and T. Lea, “EP receptor expression in human intestinal epithelium and localization relative to the stem cell zone of the crypts,” PLoS ONE, vol. 6, no. 10, Article ID e26816, 2011. View at: Publisher Site | Google Scholar
  120. K.-I. Tanaka, S. Suemasu, T. Ishihara, Y. Tasaka, Y. Arai, and T. Mizushima, “Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis,” European Journal of Pharmacology, vol. 603, no. 1–3, pp. 120–132, 2009. View at: Publisher Site | Google Scholar
  121. M. Okayama, S. Hayashi, Y. Aoi, H. Nishio, S. Kato, and K. Takeuchi, “Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats,” Digestive Diseases and Sciences, vol. 52, no. 9, pp. 2095–2103, 2007. View at: Publisher Site | Google Scholar
  122. T. G. Tessner, S. M. Cohn, S. Schloemann, and W. F. Stenson, “Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice,” Gastroenterology, vol. 115, no. 4, pp. 874–882, 1998. View at: Publisher Site | Google Scholar
  123. S. L. Brown, T. E. Riehl, M. R. Walker et al., “Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 258–269, 2007. View at: Publisher Site | Google Scholar
  124. M. Dizdaroglu, P. Jaruga, M. Birincioglu, and H. Rodriguez, “Free radical-induced damage to DNA: mechanisms and measurement,” Free Radical Biology and Medicine, vol. 32, no. 11, pp. 1102–1115, 2002. View at: Publisher Site | Google Scholar
  125. S. Kawanishi, Y. Hiraku, S. Pinlaor, and N. Ma, “Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis,” Biological Chemistry, vol. 387, no. 4, pp. 365–372, 2006. View at: Publisher Site | Google Scholar
  126. H. Kasai, “Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis,” Mutation Research - Reviews in Mutation Research, vol. 387, no. 3, pp. 147–163, 1997. View at: Publisher Site | Google Scholar
  127. P. Fortini, B. Pascucci, E. Parlanti, M. D'Errico, V. Simonelli, and E. Dogliotti, “8-oxoguanine DNA damage: at the crossroad of alternative repair pathways,” Mutation Research, vol. 531, no. 1-2, pp. 127–139, 2003. View at: Publisher Site | Google Scholar
  128. D. Wang, D. A. Kreutzer, and J. M. Essigmann, “Mutagenicity and repair of oxidative DNA damage: insights from studies using defined lesions,” Mutation Research: Fundamental and Molecular Mechanisms of Mutagenesis, vol. 400, no. 1-2, pp. 99–115, 1998. View at: Publisher Site | Google Scholar
  129. D. Calistri, C. Rengucci, I. Seymour et al., “Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression,” Journal of Cellular Physiology, vol. 204, no. 2, pp. 484–488, 2005. View at: Publisher Site | Google Scholar
  130. H. Solomon, R. Brosh, Y. Buganim, and V. Rotter, “Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis,” Discovery Medicine, vol. 9, no. 48, pp. 448–454, 2010. View at: Google Scholar
  131. Y. Kinouchi, N. Hiwatashi, M. Chida et al., “Telomere shortening in the colonic mucosa of patients with ulcerative colitis,” Journal of Gastroenterology, vol. 33, no. 3, pp. 343–348, 1998. View at: Publisher Site | Google Scholar
  132. J. N. O'Sullivan, M. P. Bronner, T. A. Brentnall et al., “Chromosomal instability in ulcerative colitis is related to telomere shortening,” Nature Genetics, vol. 32, no. 2, pp. 280–284, 2002. View at: Publisher Site | Google Scholar
  133. R. F. Willenbucher, S. J. Zelman, L. D. Ferrell, D. H. Moore II, and F. M. Waldman, “Chromosomal alterations in ulcerative colitis-related neoplastic progression,” Gastroenterology, vol. 113, no. 3, pp. 791–801, 1997. View at: Publisher Site | Google Scholar
  134. R. A. Risques, L. A. Lai, C. Himmetoglu et al., “Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation,” Cancer Research, vol. 71, no. 5, pp. 1669–1679, 2011. View at: Publisher Site | Google Scholar
  135. E. Nagy, M. Zeisig, K. Kawamura et al., “DNA adduct and tumor formations in rats after intratracheal administration of the urban air pollutant 3-nitrobenzanthrone,” Carcinogenesis, vol. 26, no. 10, pp. 1821–1828, 2005. View at: Publisher Site | Google Scholar
  136. S. D. Cline, J. N. Riggins, S. Tornaletti, L. J. Marnett, and P. C. Hanawalt, “Malondialdehyde adducts in DNA arrest transcription by T7 RNA polymerase and mammalian RNA polymerase II,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 19, pp. 7275–7280, 2004. View at: Publisher Site | Google Scholar
  137. P. M. Eckl, “Genotoxicity of HNE,” Molecular Aspects of Medicine, vol. 24, no. 4-5, pp. 161–165, 2003. View at: Publisher Site | Google Scholar
  138. I.-Y. Yang, G. Chan, H. Miller et al., “Mutagenesis by acrolein-derived propanodeoxyguanosine adducts in human cells,” Biochemistry, vol. 41, no. 46, pp. 13826–13832, 2002. View at: Publisher Site | Google Scholar
  139. S.-M. Hou, P. Nori, J.-L. Fang, and C. E. Vaca, “Methylglyoxal induces hprt mutation and DNA adducts in human T-lymphocytes in vitro,” Environmental and Molecular Mutagenesis, vol. 26, no. 4, pp. 286–291, 1995. View at: Publisher Site | Google Scholar
  140. L. A. VanderVeen, M. F. Hashim, Y. Shyr, and L. J. Marnett, “Induction of frameshift and base pair substitution mutations by the major DNA adduct of the endogenous carcinogen malondialdehyde,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 2, pp. 14247–14252, 2003. View at: Publisher Site | Google Scholar
  141. S. Choudhury, J. Pan, S. Amin, F.-L. Chung, and R. Roy, “Repair kinetics of trans-4-Hydroxynonenal-induced cyclic 1,N2-propanodeoxyguanine DNA adducts by human cell nuclear extracts,” Biochemistry, vol. 43, no. 23, pp. 7514–7521, 2004. View at: Publisher Site | Google Scholar
  142. H. Huang, H. Wang, R. S. Lloyd, C. J. Rizzo, and M. P. Stone, “Conformational interconversion of the trans-4-hydroxynonenal-derived (6S,8R,11S) 1,N2-deoxyguanosine adduct when mismatched with deoxyadenosine in DNA,” Chemical Research in Toxicology, vol. 22, no. 1, pp. 187–200, 2009. View at: Publisher Site | Google Scholar
  143. S. Giunta, R. Belotserkovskaya, and S. P. Jackson, “DNA damage signaling in response to double-strand breaks during mitosis,” Journal of Cell Biology, vol. 190, no. 2, pp. 197–207, 2010. View at: Publisher Site | Google Scholar
  144. S. Burdak-Rothkamm, K. Rothkamm, and K. M. Prise, “ATM acts downstream of ATR in the DNA damage response signaling of bystander cells,” Cancer Research, vol. 68, no. 17, pp. 7059–7065, 2008. View at: Publisher Site | Google Scholar
  145. H. Zhao, F. Traganos, and Z. Darzynkiewicz, “Kinetics of the UV-induced DNA damage response in relation to cell cycle phase. Correlation with DNA replication,” Cytometry Part A, vol. 77, no. 3, pp. 285–293, 2010. View at: Publisher Site | Google Scholar
  146. K. A. Cimprich and D. Cortez, “ATR: an essential regulator of genome integrity,” Nature Reviews Molecular Cell Biology, vol. 9, no. 8, pp. 616–627, 2008. View at: Publisher Site | Google Scholar
  147. M. L. Agarwal, W. R. Taylor, M. V. Chernov, O. B. Chernova, and G. R. Stark, “The p53 network,” Journal of Biological Chemistry, vol. 273, no. 1, pp. 1–4, 1998. View at: Publisher Site | Google Scholar
  148. H. J. Kim and S. K. Chang, “p53 mutation in patients with ulcerative colitis in rectal biopsy,” The Korean Journal of Internal Medicine, vol. 13, no. 2, pp. 110–116, 1998. View at: Publisher Site | Google Scholar
  149. S. P. Hussain, P. Amstad, K. Raja et al., “Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease,” Cancer Research, vol. 60, no. 13, pp. 3333–3337, 2000. View at: Google Scholar
  150. V. S. Kotakadi, Y. Jin, A. B. Hofseth et al., “Ginkgo biloba extract EGb 761 has anti-inflammatory properties and ameliorates colitis in mice by driving effector T cell apoptosis,” Carcinogenesis, vol. 29, no. 9, pp. 1799–1806, 2008. View at: Publisher Site | Google Scholar
  151. H. S. El-Abhar, L. N. A. Hammad, and H. S. A. Gawad, “Modulating effect of ginger extract on rats with ulcerative colitis,” Journal of Ethnopharmacology, vol. 118, no. 3, pp. 367–372, 2008. View at: Publisher Site | Google Scholar
  152. S. A. Mirbagheri, B. G. Nezami, S. Assa, and M. Hajimahmoodi, “Rectal administration of d-α tocopherol for active ulcerative colitis: a preliminary report,” World Journal of Gastroenterology, vol. 14, no. 39, pp. 5990–5995, 2008. View at: Publisher Site | Google Scholar
  153. D. Korenaga, F. Takesue, K. Kido et al., “Impaired antioxidant defense system of colonic tissue and cancer development in dextran sulfate sodium-induced colitis in mice,” Journal of Surgical Research, vol. 102, no. 2, pp. 144–149, 2002. View at: Publisher Site | Google Scholar
  154. S. S. Khanzode, S. D. Khanzode, and G. N. Dakhale, “Serum and plasma concentration of oxidant and antioxidants in patients of Helicobacter pylori gastritis and its correlation with gastric cancer,” Cancer Letters, vol. 195, no. 1, pp. 27–31, 2003. View at: Publisher Site | Google Scholar
  155. F. Farinati, R. Cardin, P. Degan et al., “Oxidative DNA damage accumulation in gastric carcinogenesis,” Gut, vol. 42, no. 3, pp. 351–356, 1998. View at: Publisher Site | Google Scholar
  156. S. S. Bhagat, R. A. Ghone, A. N. Suryakar, and P. S. Hundekar, “Lipid peroxidation and antioxidant vitamin status in colorectal cancer patients,” Indian Journal of Physiology and Pharmacology, vol. 55, no. 1, pp. 72–76, 2011. View at: Google Scholar
  157. C.-C. Yeh, C.-Y. Lai, L.-L. Hsieh, R. Tang, F.-Y. Wu, and F.-C. Sung, “Protein carbonyl levels, glutathione S-transferase polymorphisms and risk of colorectal cancer,” Carcinogenesis, vol. 31, no. 2, Article ID bgp286, pp. 228–233, 2010. View at: Publisher Site | Google Scholar
  158. S. Mehrabi, L. Wallace, S. Cohen, X. Yao, and F. O. Aikhionbare, “Differential measurements of oxidatively modified proteins in colorectal adenopolyps,” International Journal of Clinical Medicine, vol. 6, no. 4, pp. 289–299, 2015. View at: Publisher Site | Google Scholar
  159. E. Skrzydlewska, A. Stankiewicz, M. Sulkowska, S. Sulkowski, and I. Kasacka, “Antioxidant status and lipid peroxidation in colorectal cancer,” Journal of Toxicology and Environmental Health Part A, vol. 64, no. 3, pp. 213–222, 2001. View at: Publisher Site | Google Scholar
  160. E. Skrzydlewska, S. Sulkowski, M. Koda, B. Zalewski, L. Kanczuga-Koda, and M. Sulkowska, “Lipid peroxidation and antioxidant status in colorectal cancer,” World Journal of Gastroenterology, vol. 11, no. 3, pp. 403–406, 2005. View at: Publisher Site | Google Scholar
  161. T. Otamiri and R. Sjodahl, “Increased lipid peroxidation in malignant tissues of patients with colorectal cancer,” Cancer, vol. 64, no. 2, pp. 422–425, 1989. View at: Google Scholar
  162. C. Leuratti, M. A. Watson, E. J. Deag et al., “Detection of malondialdehyde DNA adducts in human colorectal mucosa: relationship with diet and the presence of adenomas,” Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 3, pp. 267–273, 2002. View at: Google Scholar
  163. N. Mistry, R. J. Bevan, M. S. Cooke et al., “Antiserum detection of reactive carbonyl species-modified DNA in human colonocytes,” Free Radical Research, vol. 42, no. 4, pp. 344–353, 2008. View at: Publisher Site | Google Scholar
  164. A. Schaeferhenrich, G. Beyer-Sehlmeyer, G. Festag et al., “Human adenoma cells are highly susceptible to the genotoxic action of 4-hydroxy-2-nonenal,” Mutation Research: Fundamental and Molecular Mechanisms of Mutagenesis, vol. 526, no. 1-2, pp. 19–32, 2003. View at: Publisher Site | Google Scholar
  165. J. Pan, J. Keffer, A. Emami et al., “Acrolein-derived DNA adduct formation in human colon cancer cells: its role in apoptosis induction by docosahexaenoic acid,” Chemical Research in Toxicology, vol. 22, no. 5, pp. 798–806, 2009. View at: Publisher Site | Google Scholar
  166. E. Eder and Budiawan, “Cancer risk assessment for the environmental mutagen and carcinogen crotonaldehyde on the basis of TD(50) and comparison with 1,N(2)-propanodeoxyguanosine adduct levels,” Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 8, pp. 883–888, 2001. View at: Google Scholar
  167. E. Eder, C. Hoffman, H. Bastian, C. Deininger, and S. Scheckenbach, “Molecular mechanisms of DNA damage initiated by α,β-unsaturated carbonyl compounds as criteria for genotoxicity and mutagenicity,” Environmental Health Perspectives, vol. 88, pp. 99–106, 1990. View at: Google Scholar

Copyright © 2016 Zhiqi Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

2466 Views | 1181 Downloads | 32 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.